Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for RLAY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 -212.20M
March 31, 2026 -213.36M
December 31, 2025 -235.46M
September 30, 2025 -248.46M
June 30, 2025 -261.42M
March 31, 2025 -271.99M
December 31, 2024 -249.11M
September 30, 2024 -280.43M
June 30, 2024 -280.74M
March 31, 2024 -283.51M
December 31, 2023 -300.32M
September 30, 2023 -268.21M
June 30, 2023 -258.96M
March 31, 2023 -247.45M
Date Value
December 31, 2022 -229.49M
September 30, 2022 -212.12M
June 30, 2022 -199.17M
March 31, 2022 -170.22M
December 31, 2021 -74.41M
September 30, 2021 -69.97M
June 30, 2021 -40.81M
March 31, 2021 -33.52M
December 31, 2020 -102.49M
September 30, 2020 -89.98M
June 30, 2020 -83.44M
March 31, 2020 -77.65M
December 31, 2019 -66.13M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
AbbVie, Inc. 19.51B
TG Therapeutics, Inc. 17.88M
Karyopharm Therapeutics, Inc. -65.35M
Krystal Biotech, Inc. 272.34M
Akebia Therapeutics, Inc. 41.55M